Nevanac Related Published Studies
Well-designed clinical trials related to Nevanac (Nepafenac Ophthalmic)
Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative
macular edema after uneventful phacoemulsification. [2012]
Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema
after cataract surgery. [2011]
Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. [2009.10]
Effects of topical nepafenac on corneal epithelial healing time and postoperative pain after PRK: a bilateral, prospective, randomized, masked trial. [2008.04]
Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery. [2007.12]
Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. [2007.11]
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. [2007.09]
Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. [2007.07]
Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. [2007.01]
Comparison of the analgesic efficacy and safety of nepafenac ophthalmic suspension compared with diclofenac ophthalmic solution for ocular pain and photophobia after excimer laser surgery: a phase II, randomized, double-masked trial. [2006.04]
Well-designed clinical trials possibly related to Nevanac (Nepafenac Ophthalmic)
NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. [2010.02]
Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). [2007.11]
Other research related to Nevanac (Nepafenac Ophthalmic)
Topical nepafenac after intravitreal injection: a prospective double-masked
randomized controlled trial. [2014]
Topical nepafenac after intravitreal injection: a prospective double-masked
randomized controlled trial. [2014]
A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. [2011.12]
Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients. [2011.12]
Prostaglandin E(2) Inhibition of Ketorolac 0.45%, Bromfenac 0.09%, and Nepafenac 0.1% in Patients Undergoing Phacoemulsification. [2011.11.18]
ROLE OF TOPICAL NEPAFENAC IN PREVENTION AND TREATMENT OF MACULAR EDEMA AFTER VITREORETINAL SURGERY. [2011.09.16]
Nepafenac 0.1% versus fluorometholone 0.1% for preventing cystoid macular edema after cataract surgery. [2011.09]
Nepafenac-assisted mydriasis in a rabbit model. [2010.10]
The effects of nepafenac and amfenac on retinal angiogenesis. [2010.02.15]
Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. [2010.01]
Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity
after cataract surgery in patients at low risk for cystoid macular oedema. [2010]
Nepafenac-associated bilateral corneal melt after photorefractive keratectomy. [2009.09]
Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. [2009.02.20]
Inhibition of surgically induced miosis and prevention of postoperative macular edema with nepafenac. [2009]
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. [2009]
Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. [2008.12]
Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients. [2008.11]
Effect of nepafenac sodium 0.1% on delayed corneal epithelial healing and haze after photorefractive keratectomy: retrospective comparative study. [2008.09]
Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. [2008.03]
Cystoid and diabetic macular edema treated with nepafenac 0.1%. [2007.12]
Nepafenac-associated corneal melt. [2007.11]
Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. [2007.09]
Case of corneal melting associated with the use of topical nepafenac. [2007.09]
The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. [2007.09]
Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. [2007.07]
Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. [2007.07]
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. [2007.02]
Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. [2006.02]
Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. [2003.10]
Topical nepafenac inhibits ocular neovascularization. [2003.01]
Other possibly related research studies
Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. [2007.02]
Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. [2003.06]
NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid
macular edema. [2010]
Efficacy and safety of pain relief medications after photorefractive keratectomy:
review of prospective randomized trials. [2014]
|